Meneldor Nieuws – Meneldor

Atriva Therapeutics Announces Changes to Management

Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19

Aptamer Group, Mologic Ink Deal to Develop Coronavirus Antigen Test

LightOx: Developing new therapeutic solutions to improve patients function and long term outcomes with oral cancer

Atriva Therapeutics Announces Changes to Advisory Board

Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin

Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente

Germany: EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

FOR MORE INFORMATION PLEASE CONTACT US